Butyrfentanyl

Butyrfentanyl is a potent, short-acting synthetic opioid analgesic and a methylated analog of fentanyl. It was first synthesized in 1961 by Janssen Pharmaceuticals as part of research into new opioid analgesics. Butyrfentanyl acts primarily as an agonist at the mu opioid receptor (μ-opioid receptor), with additional activity at kappa and delta opioid receptors. Its potency is approximately 1/30 that of fentanyl and about 1.5 times that of morphine[1][5][7]. The drug has no approved medical use and is not indicated for any clinical condition; instead, it has surfaced on the illicit market as a recreational drug[1][6]. Like other opioids, it produces effects such as analgesia (pain relief), euphoria, sedation, respiratory depression, constipation, nausea/vomiting, cognitive impairment, and itching[6]. Butyrfentanyl carries significant risks for abuse and dependence similar to other controlled opioids like morphine or fentanyl[5]. Fatalities have been reported due to its use[1][5], leading to its classification as a Schedule I controlled substance in many jurisdictions.

Other names

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamidebutyrylfentanyl